Both polyclonal (Fli-1p) and monoclonal (Fli-1m) antibodies are available.
Among small round cell tumours, it is specific to Ewing sarcoma/PNET and lymphoblastic lymphoma:
|
29/411 |
||
0/321 |
|||
Neuroblastoma |
0/301 |
||
0/81 |
|||
7/81 |
|||
Estheioneuroblastoma |
0/81 |
||
1/11 |
|||
Mesenchymal chondrosarcoma |
0/11 |
||
The sensitivity and specificity of polyclonal (Fli-1p) and monoclonal (Fli-1m) anti-Fli-1, CD99 and FISH with the EWSR1 (22q12) dual-colour break-apart probe have been compared6. In normal tissues, Fli-1p expression was restricted to haemopoietic and endothelial cells. However, Fli-1m was also expressed by the prostate, breast , colon and squamous epithelium.
For each antibody, a threshold of 10% of tumour cells staining was set, cytoplasmic for CD99 and nuclear for Fli-1. |
||||
40/436 |
3/156 |
0.876 |
||
Fli-1m |
42/436 |
6/156 |
0.796 |
|
Fli-1p |
35/436 |
2/156 |
0.846 |
|
CD99+Fli-1m |
40/436 |
3/156 |
0.886 |
|
CD99+Fli-1p |
40/436 |
4/156 |
0.916 |
|
Fli-1m+Fli-1p |
42/436 |
6/156 |
0.896 |
|
CD99+Fli-1m+Fli-1p |
40/436 |
4/156 |
0.936 |
|
FISH |
19/386 |
0/156 |
|
|
In conclusion, Fli-1m is sensitive but lacks specificity for EWS/PNET. The combination of CD99 and Fli-1p is optimal.
endothelial cells and vascular tumours2:
20/222 |